表紙
市場調査レポート

糖尿病:KOLの洞察およびコンセンサスの展望

Diabetes -- KOL Insight and Consensus Outlook Modules

発行 FirstWord 商品コード 284609
出版日 ページ情報 英文 224 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
糖尿病:KOLの洞察およびコンセンサスの展望 Diabetes -- KOL Insight and Consensus Outlook Modules
出版日: 2014年02月27日 ページ情報: 英文 224 Pages
概要

肥満レベルおよび糖尿病の罹患率は、先進・新興市場のどちらにおいても上昇しており、5年間のCAGRは12%以上で2012年の市場額は319億米ドルに達しました。2030年までに糖尿病の患者数は約2倍の3億4,700万人(90%は2型糖尿病患者)になると予測されています。糖尿病市場は5カ年のCAGRが11%で成長し、540億米ドル規模に達すると予測されています。同市場における主要4社はNovo Nordisk、Sanofi、Eli Lilly および Merck となっています。

当レポートでは、糖尿病市場の包括的レビューと米国・欧州有数のKOLに対する独占インタビューを提供するKOLの洞察(KOL Insight)モジュール、および製品レベルの販売データの年間実績と予測を提供するデータ分析モジュールを、概略以下の構成でお届けします。

KOL(キーオピニオンリーダー)の洞察

  • KOL洞察レポート
    • 世界の糖尿病市場における現在および予測される治療動向、臨床製品、および商業的変化の定性分析の提供:一流の臨床医の詳細な専門的見解による
    • 糖尿病市場動向の背景における市場の主要企業、製品、後期開発段階のパイプライン治療薬、製品ポジショニングの比較
  • イベントビュレティン
    • 糖尿病治療動向の変化を促進する重要なイベントについての最新のKOLの見解

コンセンサスの展望

  • コンセンサスレポート
    • 一流アナリスト・仲介企業によって選ばれた主な糖尿病市場予測のパラメーターにおいて予測される定性量的変化についての詳細な5カ年のコンセンサス展望
    • 糖尿病市場規模、製品売上、企業別の市場シェア、競合状況および詳細な市場予測のチャート
  • インタラクティブExcelファイル
    • 主要動向を掘り下げ、評価するための詳細な市場・製品販売データ

目次

  • コンテンツ
  • FirstWord の分析ハイライト
  • 調査手法
  • 糖尿病市場
  • 主な糖尿病治療薬ディベロッパー
  • 糖尿病のクラス別動向
  • Lantus (インスリングラルギン; Sanofi) 予測
  • Levemir (インスリンデテミル; Novo Nordisk) 予測.
  • Tresiba (インスリンデグルデク; Novo Nordisk) 予測
  • Ryzodeg (degludecPlus; Novo Nordisk) 予測
  • NovoRapid/NovoLog (インスリンアスパルト; Novo Nordisk) 予測
  • Humalog (インスリン リスプロ; Eli Lilly) 予測
  • Apidra (インスリングルリジン; Sanofi) 予測.
  • NovoMix/NovoLog Mix (インスリンアスパルト + インスリンアスパルトプロタミン; Novo Nordisk) 予測
  • Januvia franchise (シタグリプチン; Merck & Co) 予測
  • Galvus franchise (ビルダグリプチン; Novartis) 予測
  • Onglyza franchise (ビルダグリプチン; Bristol-Myers Squibb/AstraZeneca/ 大塚製薬) 予測
  • Nesina franchise (アルゴリプチン; 武田薬品工業) 予測
  • Tradjenta franchise (リナグリプチン; Boehringer Ingelheim/Eli Lilly) 予測
  • Byetta (エクセナチド; Bristol-Myers Squibb/AstraZeneca/Amylin) 予測
  • Bydureon (エクセナチド once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) 予測
  • Victoza (リラグルチド; Novo Nordisk) 予測
  • Lyxumia (リキセナチド; Sanofi) 予測.
  • Invokana (カナグリフロジン; Johnson & Johnson/田辺三菱製薬) 予測
  • Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) 予測
  • Actos (ピオグリタゾン; 武田薬品工業) 予測
  • U300 (インスリングラルギン; Sanofi) 予測
  • LY2605541 (インスリンペグリスプロ; Eli Lilly) 予測
  • LY2963016 (バイオシミラーインスリングラルジン; Eli Lilly/Boehringer Ingelheim) 予測
  • IDeglira (リラグルチド + インスリンデグルデク; Novo Nordisk) 予測
  • Afrezza (Technosphere Insulin; MannKind Corporation) 予測
  • FIAsp (インスリンアスパルト; Novo Nordisk) 予測.
  • Eperzan (アルビグルチド; GlaxoSmithKline/Human Genome Sciences) 予測
  • LY2189265 (dulaglutide; Eli Lilly) 予測
  • BI-10773 (エンパリフロジン; Boehringer Ingelheim/Eli Lilly) 予測

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The medium term: battle lines are drawn

The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established and emerging markets have seen the sector return a 5 year compound annual growth rate (CAGR) of over 12% to reach US$31.9 billion in 2012. It is estimated that 347 million people have the disease - 90% of whom are Type II diabetes sufferers - and this figure could almost double by 2030.

The big four companies in diabetes - Novo Nordisk, Sanofi, Eli Lilly and Merck - are locked in a battle for supremacy which is set to continue over the medium term. While Novo Nordisk currently leads the pack, Sanofi is close behind. With Novo Nordisk's approval of Tresiba (insulin degedec) stalled in the US over safety concerns, Sanofi latest version of Lantus U300 (insulin glargine) could capitalise. Bristol Myers-Squibb and AstraZeneca are just two of the other players set to increase their sales significantly in this busy marketplace by 2017.

The diabetes market will continue on an upward trajectory, and an estimated 5 year CAGR of 11% will see the sector top US$54 billion - the question is which companies will have a slice to this market, and how big will it be?

What's in the pipeline?

Finding market voice for new products in diabetes depends critically on price and differentiation. Cost of treatment is already an issue and resistance can be expected from health payers if new products offer only marginal therapeutic or patient management benefits. For example, excitement about Sanofi's U300 (insulin glargine) is because it shows differentiation to Lantus with "peakless" delivery and longer duration. Eli Lilly's weekly dose dulaglutide may offer advantages over other launched and pipeline GLP-1 products such as such as GSK's Eperzan (albiglutide) and BMS/AZ/Amylin's Bydureon (exanatide) but meaningful advantages need to be shown for success in the market.

What the Future Holds: is there a Game Changer on the Horizon?

Don't expect a revolution in diabetes treatment soon. New products coming to market are essentially incremental improvements over current approaches, with better safety profiles and geared to improving patient compliance.

The real prize will be for the company that can bring a paradigm shift to the treatment of diabetes. Upsetting the status quo will require a fundamentally different approach - and some of these developments threaten the diabetes drugs manufacturers existing revenues.

Among the developments to be aware of are the threat of biosimilars, the development of an artificial pancreas 'closed loop' system, the wide implementation of which would be a doomsday development for drugs companies, and a DNA reverse vaccine for which early clinical results have shown promise.

A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than FirstWord's Therapy Trends: Diabetes. This comprehensive FirstWord research is available in two comprehensive modules:

  • The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
  • The Consensus Outlook: Diabetes data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections

KOL Insight

KOL Insight Report

  • A 220-page qualitative analysis of the current and predicted treatment trends, clinical products and commercial changes in the global diabetes market informed by in-depth expert views of leading clinicians
  • Compare the market's key players, products, late-stage pipeline drugs, product positioning, in the context of Diabetes market trends

Event Bulletins

  • Benefit from the latest KOL views about significant event driven changes in diabetes treatment trends

Consensus Outlook

Consensus Report

  • An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key Diabetes market forecast parameters drawn from 13 leading analyst and brokerage companies
  • Chart diabetes market size, product sales, market share by company, competitive status and detailed market forecasts

Interactive Analytics File

  • Use the interactive Excel market analytics module of detailed market and product sales data from 2007 to 2017 to drill down and assess key trends.

Table of Contents

  • Contents
  • FirstWord Analysis Highlights.
  • Research Methodology
  • Diabetes Marketplace
  • Key Diabetes Developers
  • Diabetes Class Dynamics
  • Lantus (insulin glargine; Sanofi) forecast
  • Levemir (insulin detemir; Novo Nordisk) forecast.
  • Tresiba (insulin degludec; Novo Nordisk) forecast
  • Ryzodeg (degludecPlus; Novo Nordisk) forecast
  • NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
  • Humalog (insulin lispro; Eli Lilly) forecast
  • Apidra (insulin glulisine; Sanofi) forecast.
  • NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
  • Januvia franchise (sitagliptin; Merck & Co) forecast
  • Galvus franchise (vildagliptin; Novartis) forecast
  • Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
  • Nesina franchise (alogliptin; Takeda) forecast
  • Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
  • Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
  • Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
  • Victoza (liraglutide; Novo Nordisk) forecast
  • Lyxumia (lixisenatide; Sanofi) forecast.
  • Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
  • Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
  • Actos (pioglitazone; Takeda) forecast
  • U300 (insulin glargine; Sanofi) forecast
  • LY2605541 (insulin peglispro; Eli Lilly) forecast
  • LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
  • IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
  • Afrezza (Technosphere Insulin; MannKind Corporation) forecast
  • FIAsp (insulin aspart; Novo Nordisk) forecast.
  • Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
  • LY2189265 (dulaglutide; Eli Lilly) forecast
  • BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast
Back to Top